Order Article Reprints

Al Khzem AH, Shoaib TH, Mukhtar RM, Alturki MS, Gomaa MS, Hussein D, Tawfeeq N, Bano M, Sarafroz M, Alzahrani R, et al. Repurposing FDA-Approved Agents to Develop a Prototype Helicobacter pylori Shikimate Kinase (HPSK) Inhibitor: A Computational Approach Using Virtual Screening, MM-GBSA Calculations, MD Simulations, and DFT Analysis. Pharmaceuticals. 2025; 18(2):174. https://doi.org/10.3390/ph18020174

Al Khzem, Abdulaziz H., Tagyedeen H. Shoaib, Rua M. Mukhtar, Mansour S. Alturki, Mohamed S. Gomaa, Dania Hussein, Nada Tawfeeq, Mohsina Bano, Mohammad Sarafroz, Raghad Alzahrani, and et al. 2025. "Repurposing FDA-Approved Agents to Develop a Prototype Helicobacter pylori Shikimate Kinase (HPSK) Inhibitor: A Computational Approach Using Virtual Screening, MM-GBSA Calculations, MD Simulations, and DFT Analysis" Pharmaceuticals 18, no. 2: 174. https://doi.org/10.3390/ph18020174

Al Khzem, A. H., Shoaib, T. H., Mukhtar, R. M., Alturki, M. S., Gomaa, M. S., Hussein, D., Tawfeeq, N., Bano, M., Sarafroz, M., Alzahrani, R., Alghamdi, H., & Rants’o, T. A. (2025). Repurposing FDA-Approved Agents to Develop a Prototype Helicobacter pylori Shikimate Kinase (HPSK) Inhibitor: A Computational Approach Using Virtual Screening, MM-GBSA Calculations, MD Simulations, and DFT Analysis. Pharmaceuticals, 18(2), 174. https://doi.org/10.3390/ph18020174